• Active cancer treatment: Monitoring tumour activity and molecular change during therapy.
• Post-treatment surveillance: Monitoring for recurrence or disease progression in cancer survivors.
• Baseline molecular profiling: Establishing circulating tumour biomarkers prior to treatment initiation.
• Treatment response assessment: Evaluating effectiveness of chemotherapy, targeted therapy or immunotherapy.
• Emerging resistance: Identifying molecular changes that may influence ongoing treatment strategy.

Overview

Cancertrack™ Monitoring is a blood-based test that analyses circulating tumour DNA (ctDNA) and circulating tumour cells (CTCs), providing liquid biopsy insight into tumour activity during the course of disease. These biomarkers can reflect changes in tumour burden and underlying molecular behaviour.

Tracking these markers may help identify early signs of disease progression, recurrence or developing treatment resistance. This information can support more timely clinical decisions during active treatment or follow-up.

Results are interpreted alongside imaging findings, tumour subtype, treatment history and overall oncological assessment. Reviewing molecular trends within this broader clinical context may help guide therapy adjustment, monitoring intervals and longer-term disease management.

Practical

Specimen

Whole blood 

Container

• 2 x DCGL Streck tubes
• 2 x EDTA tubes (purple colour cap) of 10 ml each

Volume

15-20 mL

Patient preparation

Require 5-6 hours fasting prior collection